Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD)-Reference-Cited by-同舟云学术

Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD)

Published:2023-04-16 Issue:8 Volume:23 Page:791-800
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Bokemeyer Bernd¹^ORCID,Hlavaty Tibor²,Allez Matthieu³^ORCID,Selema Pamela⁴,Moosavi Shahrzad⁴,Cadatal Mary Jane⁵,Fowler Heather⁶,Mueller Markus⁷,Liau Katherine F⁸,Gisbert Javier P⁹^ORCID

Affiliation:

1. Interdisciplinary Crohn Colitis Centre Minden, Minden, Germany

2. 5th Department of Internal Medicine, Sub-department of Gastroenterology and Hepatology, University Hospital Bratislava and Comenius University, Bratislava, Slovakia

3. Gastroenterology Department, Hôpital Saint-Louis - APHP, INSERM U1160, Université De Paris, Paris, France

4. Worldwide Safety and Risk Management, Pfizer, Inc, New York City, NY, USA

5. Global Biometrics and Data Management, Pfizer, Inc, Manila, Philippines

6. Clinical Development and Operations, Pfizer, Inc, London, UK

7. Medical Affairs, Pfizer, Pharma GmbH, Berlin, Germany

8. Biosimilars, Pfizer, Inc, La Jolla, CA, USA

9. Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain

Funder

Hospira, Inc., which was acquired by Pfizer, Inc., in September 2015

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2023.2200883

Reference31 articles.

1. Inflammatory bowel disease: clinical aspects and treatments

2. Biologic therapies in inflammatory bowel disease

Remicade^® (infliximab): 20 years of contributions to science and medicine

4. US Food and Drug Administration (FDA). Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry; 2015 [cited 2020 15 Feb]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf

5. US Food and Drug Administration (FDA). Patient materials, biosimilars; 2019 [cited 2020 5 Mar]. Available from: https://www.fda.gov/drugs/biosimilars/patient-materials

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical experience of using biosimilars in Crohn’s disease and their effectiveness;Expert Opinion on Biological Therapy;2024-09-13